Ashland(NYSE) ASH

Ashland makes ingredients that help everyday items work better. Their chemicals make pills easier to swallow and help paint stick to walls. They serve companies in the health, beauty, and building industries.

Science Behind Everyday Items

• Cellulosics: Plant-based thickeners and binders used in medicines, food, and construction; accounts for 41% of total sales in Q2 2026.
• Polyvinylpyrrolidones: Synthetic polymers that help stabilize medicines and care products; represents 23% of total sales in Q2 2026.
• Life Sciences: Ingredients for medicines and food, like coatings that control how pills release into the body.
• Personal Care: Nature-based ingredients for toothpaste, hair care, and skin products that moisturize or protect.
• Specialty Additives: Chemicals for construction and automotive markets, including additives that improve how paint and mortars flow.

Strategic Reshaping

• Sold the Avoca business to Mane SA in March 2025 for $16 million to optimize its segment portfolio.
• Initiated the 2025 Restructuring Program to improve manufacturing costs and offset impacts from previous business sales.
• Completed the sale of excess land for $4 million in net proceeds during the six months ended March 31, 2026.
• Advanced a multi-year plan to optimize its manufacturing network and strengthen its global competitive position.

What Makes Ashland Different?

Ashland maintains a specialized focus on plant-based and synthetic polymers that serve highly regulated markets like pharmaceuticals and nutrition. The company uses chemical engineering to create nature-derived ingredients that meet growing demand for biodegradable products.

By the Numbers

• Sales reached $482 million in Q2 2026, up 0.6% from $479 million in Q2 2025.
• Net income was $16 million in Q2 2026, down 48.4% from $31 million in Q2 2025.
• Free cash flow turned positive at $24 million in Q2 2026, up 220% from a $20 million loss in Q2 2025.
• Operating income fell to $39 million in Q2 2026, a 23.5% decrease from $51 million in Q2 2025.
• The company held $343 million in cash and cash equivalents as of March 31, 2026.

The Final Word

Ashland has transitioned into a focused specialty materials company by selling non-core segments and optimizing its manufacturing footprint. Its focus on pharmaceutical and personal care ingredients helps it maintain a presence in stable consumer markets.